LoValTech
LoValTech is a French DeepTech biotech developing nasal protein subunit vaccines via a proprietary mucosal delivery platform. Its lead candidate LVT-001/MUCOBOOST targets COVID-19 in Phase II trials, with commercialization planned through pharmaceutical licensing and sales to healthcare systems and governments.
- Company typePrivate
- Founded2022
- HeadquartersVal-de-roulans, France
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What LoValTech does
LoValTech is a French DeepTech biotech startup, founded in January 2022 as a spin-off from the BioMAP research team (UMR ISP 1282) at the University of Tours and INRAE, headquartered in Tours, France. The company develops nasal protein subunit vaccines built around three integrated technology components: a multivalent fusion protein (SwFN) combining SARS-CoV-2 Spike and Nucleocapsid, proprietary mucosal nanocarriers, and a novel muco-excipient delivery system that is adjuvant-free and stable at positive temperatures. The lead candidate, LVT-001 (MUCOBOOST), is a nasal COVID-19 vaccine designed to induce both systemic IgG and mucosal IgA responses, with the goal of achieving sterilizing immunity and blocking viral transmission at the respiratory entry point. Preclinical data, published in npj Vaccines (Nature), demonstrated cross-reactive immunity against variants and reduced host-to-host transmission in hamster models.
The business model is structured around three revenue streams that activate post-approval: direct vaccine sales to healthcare systems and governments, licensing and royalty agreements with pharmaceutical partners for global commercialization, and government/institutional procurement for pandemic preparedness. Manufacturing is outsourced to a network of French CDMOs (GTP Bioways for protein, Stanipharm for muco-excipient, C-Ris Pharma for preclinical studies), while nasal spray device production is being built in partnership with Aptar Pharma under the France 2030 program. The company has secured over €16 million in public funding (MESRI, ANRS-MIE, France 2030, i-Lab) plus an undisclosed seed round, and is currently raising €5M through the Tudigo crowdfunding platform. As of 2026, Phase I of the MUCOBOOST clinical trial has been successfully completed (demonstrating excellent tolerability), Phase II is underway under ANSM authorization (NCT06821126), and the broader mucosal platform is positioned for extension into influenza, bronchiolitis, malaria, oncology, and allergy indications.
LoValTech firmographics
Firmographics- Name
- LoValTech
- Legal name
- lovaltech
- Website
- https://lovaltechnology.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- LoValTech is a French DeepTech biotech developing nasal protein subunit vaccines via a proprietary mucosal delivery platform. Its lead candidate LVT-001/MUCOBOOST targets COVID-19 in Phase II trials, with commercialization planned through pharmaceutical licensing and sales to healthcare systems and governments.
- Ownership category
- akta.pro rank
LoValTech industry classification
Industry- Product category
- Nasal Vaccines
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)
- akta.pro secondary industries
- Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF), Vaccine Cold Chain, Storage & Distribution (HLAIAEAK)
Keywords
Where LoValTech is headquartered
LocationHeadquarters
- HQ city
- Val-de-roulans
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
LoValTech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Vaccine Product Sales: Revenue from direct sales of nasal vaccines to healthcare systems, governments, and distribution networks upon regulatory approval and commercialization.
- Licensing Agreements: Value-creation strategy based on clinical milestones and licensing agreements with pharmaceutical industrial partners for vaccine development and commercialization rights.
- Government/Institutional Procurement: Public funding and procurement contracts from governments and health authorities for pandemic preparedness and national vaccination programs.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
LoValTech product offering
Product offeringCore offering
LoValTech develops a new generation of nasally-administered protein subunit vaccines using a proprietary muco-excipient delivery platform combined with multivalent fusion proteins (spike and nucleoprotein). The lead product, LVT-001/MUCOBOOST, is a nasal COVID-19 vaccine designed to induce both systemic and mucosal immunity, blocking viral transmission and protecting against current and emerging variants. The platform technology is being extended to influenza, bronchiolitis, malaria, and other respiratory infectious diseases.
Product overview
LoValTech is a French DeepTech biotech company developing a new generation of nasally-administered protein vaccines. The company's flagship product is LVT-001 (MUCOBOOST), a COVID-19 nasal vaccine using a proprietary muco-excipient platform combined with a multivalent fusion protein (Spike + nucleoprotein). The platform technology enables broad-spectrum protection against variants by inducing both systemic and mucosal immunity, with the nasal spray delivery system allowing non-invasive administration. The company is advancing Phase I/II clinical trials for its lead vaccine candidate while building a versatile mucosal vaccine platform applicable to multiple diseases including influenza and malaria.
Differentiator
Problem solved
Functional benefit
Products and services
- LVT-001 / MUCOBOOST Nasal subunit vaccine against COVID-19 composed of a multivalent fusion protein (SwFN) combining Spike and nucleoprotein with biocompatible mucosal nanocarriers (Nc). Designed to induce both systemic and mucosal immunity, blocking viral transmission and protecting against current and emerging SARS-CoV-2 variants.
- Muco-excipient Platform Proprietary mucosal excipient technology enabling optimal vaccine delivery in the nasal cavity. The adjuvant-free formulation allows robust humoral and cellular immune response induction. Developed under GMP conditions.
- Nasal Spray Delivery System Non-invasive intranasal spray device for vaccine administration. Developed in collaboration with Aptar Pharma, a world leader in pharmaceutical sprays and aerosols. Enables easy self-administration without needles.
- Intranasal Spike and Nucleoprotein Fusion Protein Vaccine Broad-spectrum vaccine candidate published in npj Vaccines (Nature) demonstrating cross-protection against SARS-CoV-2 variants and reduced host-to-host transmission in preclinical models.
Quantifiable outcome
- Significant reduction in viral load and transmission demonstrated in preclinical models published in npj Vaccines (Nature)
- +4 more outcomes
Companies that use LoValTech
Customer profileSegments3 records
Ideal customer profiles2 records
LoValTech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
LoValTech partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and major.
- Aptar PharmacoreWorld leader in spray and aerosol manufacturing for pharmaceutical market. Developing unprecedented nasal spray device design per LovalTech specifications. Committed to dedicated production line in France under France 2030 program.
- BioMAP (University of Tours / INRAE)coreThe BioMAP research team (UMR ISP 1282) developed the nasal vaccine technology. LovalTech was created to pursue industrial development. Includes scientific founders Isabelle Dimier-Poisson, Mathieu Epardaud, and Nicolas Aubrey from the university team. The university team has published 30+ articles and filed 5 patents in 5 years.
- GTP BiowaysmajorContract Development and Manufacturing Organization (CDMO) for GMP production and pharmaceutical release of vaccine protein.
- StanipharmmajorCDMO for GMP production and pharmaceutical release of muco-excipient.
- C-Ris PharmamajorFrench CRO specialized in non-clinical studies. Conducted regulatory toxicity and immunogenicity studies from October 2022, now completed and validated vaccine safety.
Scale indicators11 records
Recent moves4 records
Expansion highlights6 records
LoValTech competitors and assessment
Company assessmentDirect peers
- Altimmune: Clinical-stage US biotech developing intranasal vaccines including T-COVID (AdCOVID) and NasoShield for anthrax, with direct comparison to LoValTech's mucosal vaccine platform targeting respiratory pathogens.
- Codagenix: Clinical-stage biotech using live-attenuated intranasal vaccines for COVID-19 (COVI-VAC), influenza, and RSV, with a comparable mucosal vaccine platform approach and similar target indications.
- Vaxart: Clinical-stage biotech developing oral tablet vaccines targeting mucosal immunity for COVID-19 and norovirus, competing in the same mucosal immunity differentiation thesis as LoValTech.
- CyanVac: Clinical-stage biotech developing intranasal vaccines using a proprietary platform (including a parainfluenza-based vector for respiratory syncytial virus), with comparable mucosal delivery approach.
- Meissa Vaccines: Clinical-stage biotech developing intranasal live-attenuated vaccines for RSV and COVID-19, targeting mucosal immunity at the point of viral entry similar to LoValTech's mechanism.
- CanSino Biologics: Chinese biotech that launched Convidecia Air, the first approved inhaled/admistered intranasal COVID-19 vaccine, representing the most advanced commercial competitor in the mucosal COVID vaccine space.
- Bharat Biotech: Indian vaccine manufacturer with iNCOVACC, an approved intranasal adenoviral COVID-19 vaccine, providing an established commercial benchmark for mucosal COVID vaccine commercialization.
Broad incumbents
- AstraZeneca (FluMist): Through acquisition of MedImmune, markets FluMist — the most established intranasal vaccine (live-attenuated influenza) — representing the incumbent mucosal vaccine platform against which LoValTech must differentiate.
Emerging players
- FluGen: Clinical-stage biotech developing intranasal M2SR flu vaccine that demonstrates comparable mucosal immunity approach and applies broadly to the respiratory vaccine market LoValTech targets.
- BlueWillow Biologics: Clinical-stage biotech developing intranasal vaccines using a nanoemulsion platform for infectious disease indications, an emerging competitor in the mucosal vaccine delivery space.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
LoValTech social profiles
Digital presenceLoValTech financial estimates
Financial estimateRevenue estimate
Valuation estimate
LoValTech leadership team
Management profileNumber of profiles
Profiles10 records
LoValTech funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LoValTech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LoValTech
What does LoValTech do?
LoValTech develops a new generation of nasally-administered protein subunit vaccines using a proprietary muco-excipient delivery platform combined with multivalent fusion proteins (spike and nucleoprotein). The lead product, LVT-001/MUCOBOOST, is a nasal COVID-19 vaccine designed to induce both systemic and mucosal immunity, blocking viral transmission and protecting against current and emerging variants. The platform technology is being extended to influenza, bronchiolitis, malaria, and other respiratory infectious diseases.
Is LoValTech a public or private company?
LoValTech is a private company. It is classified as venture growth investor backed and is currently operating.
When was LoValTech founded?
LoValTech was founded in 2022. It employs 1 to 10 people.
Where is LoValTech based?
LoValTech is headquartered in Val-de-roulans, France, in the Europe region.
How does LoValTech make money?
Three revenue lines are on record. Vaccine Product Sales are the primary driver. The others are licensing Agreements and government/Institutional Procurement.
Who are LoValTech's main competitors?
Direct peers on record are Altimmune, Codagenix, Vaxart, CyanVac, Meissa Vaccines, CanSino Biologics and Bharat Biotech. AstraZeneca (FluMist) is listed as a broad incumbent. Emerging players are FluGen and BlueWillow Biologics.
Does LoValTech have an API?
No public API is recorded for LoValTech.
What industry is LoValTech in?
LoValTech's product category is Nasal Vaccines. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAAAEAF, Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral). Its NAICS code is 325414 and its SIC code is 2836.